Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
GH Stock Forecast 2026-2027
$155.87
Current Price
$21.61B
Market Cap
Buy 24
Hold 0
Sell 1
Wall St Analyst Ratings
Distance to GH Price Targets
+37.9%
To High Target of $215.00
+1.0%
To Median Target of $157.50
-42.3%
To Low Target of $90.00
GH Price Momentum
-2.6%
1 Week Change
+18.3%
1 Month Change
+235.5%
1 Year Change
+52.6%
Year-to-Date Change
-10.5%
From 52W High of $174.08
+286.3%
From 52W Low of $40.35
📊 TOP ANALYST CALLS
Did GH Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Guardant Health is one of their latest high-conviction picks.
Latest GH Stock Price Targets & Analyst Predictions
Based on our analysis of 9 Wall Street analysts, GH has a bullish consensus with a median price target of $157.50 (ranging from $90.00 to $215.00). The overall analyst rating is Strong Buy (9.3/10). Currently trading at $155.87, the median forecast implies a 1.0% upside. This outlook is supported by 24 Buy, 0 Hold, and 1 Sell ratings.
The most optimistic forecast comes from Patrick Donnelly at Citigroup, projecting a 37.9% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
GH Analyst Ratings
24
Buy
0
Hold
1
Sell
GH Price Target Range
Low
$90.00
Average
$157.50
High
$215.00
Current: $155.87
Latest GH Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for GH.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jul 14, 2026 | Canaccord Genuity | Kyle Mikson | Buy | Maintains | $205.00 |
| Jul 9, 2026 | Morgan Stanley | Shannon O'Callaghan | Overweight | Maintains | $175.00 |
| Jul 8, 2026 | Citigroup | Patrick Donnelly | Buy | Maintains | $215.00 |
| Jul 6, 2026 | Evercore ISI Group | Vijay Kumar | Outperform | Maintains | $200.00 |
| Jul 6, 2026 | B of A Securities | Michael Ryskin | Buy | Maintains | $190.00 |
| Jul 2, 2026 | Bernstein | Eve Burstein | Outperform | Maintains | $200.00 |
| Jul 1, 2026 | BTIG | Buy | Maintains | $N/A | |
| Jun 29, 2026 | Guggenheim | Buy | Maintains | $N/A | |
| Jun 26, 2026 | Bernstein | Eve Burstein | Outperform | Reinstates | $175.00 |
| Jun 24, 2026 | Barclays | Overweight | Maintains | $N/A | |
| Jun 11, 2026 | RBC Capital | Outperform | Initiates | $N/A | |
| Jun 8, 2026 | Mizuho | Outperform | Maintains | $N/A | |
| Jun 5, 2026 | Goldman Sachs | Buy | Initiates | $N/A | |
| Jun 2, 2026 | Evercore ISI Group | Outperform | Upgrade | $N/A | |
| Jun 2, 2026 | Wolfe Research | Mike Polark | Outperform | Assumes | $150.00 |
| May 27, 2026 | BTIG | Buy | Maintains | $N/A | |
| May 26, 2026 | BTIG | Buy | Maintains | $N/A | |
| May 8, 2026 | JP Morgan | Overweight | Maintains | $N/A | |
| May 8, 2026 | Barclays | Overweight | Maintains | $N/A | |
| May 8, 2026 | Evercore ISI Group | In-Line | Maintains | $N/A |
Guardant Health Inc. (GH) Competitors
The following stocks are similar to Guardant Health based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
GH
Guardant Health
mkt cap
21.22B
Guardant Health Inc. (GH) Financial Data
Guardant Health Inc. has a market capitalization of $21.61B with a P/E ratio of -48.0x. The company generates $1.08B in trailing twelve-month revenue with a -40.1% profit margin.
Revenue growth is +48.3% quarter-over-quarter, while maintaining an operating margin of -40.2% and return on equity of +419.2%.
Valuation Metrics
Market Cap
$21.61B
Enterprise Value
$21.61B
P/E Ratio
-48.0x
PEG Ratio
-4.6x
Price/Sales
19.7x
Growth & Margins
Revenue Growth (YoY)
+48.3%
Gross Margin
+65.2%
Operating Margin
-40.2%
Net Margin
-40.1%
EPS Growth
+48.3%
Financial Health
Cash/Price Ratio
+5.3%
Current Ratio
4.7x
Debt/Equity
-9.4x
ROE
+419.2%
ROA
-17.1%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Guardant Health Inc. (GH) Business Model
About Guardant Health Inc.
What They Do
Develops precision oncology blood and tissue tests.
Business Model
The company generates revenue by offering genomic profiling tests for cancer patients, monitoring for minimal residual disease, and providing screening services for early cancer detection. Additionally, it collaborates with biopharmaceutical partners to offer companion diagnostic services, utilizing clinico-genomic data to enhance therapeutic development and clinical decision-making.
Additional Information
Guardant Health is headquartered in Palo Alto, California, and is positioned in the growing market for liquid biopsy and precision diagnostics, which emphasizes the use of noninvasive testing methods to improve treatment selection and cancer monitoring.
Company Information
Sector
Healthcare
Industry
Diagnostics & Research
Employees
2,490
CEO
Dr. Helmy Eltoukhy Ph.D.
Country
United States
IPO Year
2018
Website
guardanthealth.comGuardant Health Inc. (GH) Latest News & Analysis
Latest News
Quick Summary
Artisan Mid Cap Fund outperformed the Russell Midcap® Growth Index, driven by strong semiconductor returns. New positions were added in Entegris, Modine Manufacturing, and C.H. Robinson Worldwide.
Why It Matters
Strong returns from the Artisan Mid Cap Fund and semiconductor holdings indicate robust growth potential, signaling investment opportunities in mid-cap stocks and specific sectors like technology.
Source: Seeking Alpha
Market Sentiment:
Positive
Quick Summary
Guardant Health's stock rose after competitor Freenome released study results for its colon cancer blood test.
Why It Matters
Guardant Health's stock surge indicates market optimism about its competitive edge in the cancer diagnostics sector, potentially impacting future revenue and market share against Freenome.
Source: Investors Business Daily
Market Sentiment:
Positive
Quick Summary
Guardant Health, Inc. (Nasdaq: GH) will release its Q2 2026 financial results on July 30, 2026, after market close, followed by a conference call at 1:30 p.m. PT.
Why It Matters
Guardant Health's upcoming financial results announcement and conference call could impact stock prices, reflecting investor sentiment on the company's performance and future prospects.
Source: Business Wire
Market Sentiment:
Neutral
UnitedHealth Group Now Covers Guardant Health's Shield Blood Test for Colorectal Cancer Screening
17 days ago
Quick Summary
Guardant Health's Shield™ blood test for colorectal cancer screening is now covered by UnitedHealth Group for eligible members aged 45 and older, marking a significant development in CRC detection.
Why It Matters
Guardant Health's Shield™ test gaining coverage from UnitedHealth expands market access, potentially increasing revenue and growth in a crucial cancer screening segment, appealing to investors.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
TD Cowen analysts project the longevity healthcare market's total addressable value to surpass $250 billion.
Why It Matters
A $250 billion longevity healthcare market signals significant growth potential, attracting investment opportunities and influencing stock valuations in related sectors.
Source: Barrons
Market Sentiment:
Positive
Quick Summary
Gamehost Inc. has received court approval for its acquisition by Pure Casino Entertainment, with Pure's subsidiary to buy Gamehost shares at $13.65 each, following shareholder approval on June 11, 2026.
Why It Matters
Gamehost's acquisition by Pure Casino at $13.65 per share indicates a premium on its stock, signaling potential value appreciation and liquidity for shareholders.
Source: Newsfile Corp
Market Sentiment:
Neutral
Frequently Asked Questions About GH Stock
What is Guardant Health Inc.'s (GH) stock forecast for 2027?
Based on our analysis of 9 Wall Street analysts, Guardant Health Inc. (GH) has a median price target of $157.50. The highest price target is $215.00 and the lowest is $90.00.
Is GH stock a good investment in 2027?
According to current analyst ratings, GH has 24 Buy ratings, 0 Hold ratings, and 1 Sell ratings. The stock is currently trading at $155.87. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for GH stock?
Wall Street analysts predict GH stock could reach $157.50 in the next 12 months. This represents a 1.0% increase from the current price of $155.87. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Guardant Health Inc.'s business model?
The company generates revenue by offering genomic profiling tests for cancer patients, monitoring for minimal residual disease, and providing screening services for early cancer detection. Additionally, it collaborates with biopharmaceutical partners to offer companion diagnostic services, utilizing clinico-genomic data to enhance therapeutic development and clinical decision-making.
What is the highest forecasted price for GH Guardant Health Inc.?
The highest price target for GH is $215.00 from Patrick Donnelly at Citigroup, which represents a 37.9% increase from the current price of $155.87.
What is the lowest forecasted price for GH Guardant Health Inc.?
The lowest price target for GH is $90.00 from at , which represents a -42.3% decrease from the current price of $155.87.
What is the overall GH consensus from analysts for Guardant Health Inc.?
The overall analyst consensus for GH is bullish. Out of 9 Wall Street analysts, 24 rate it as Buy, 0 as Hold, and 1 as Sell, with a median price target of $157.50.
How accurate are GH stock price projections?
Stock price projections, including those for Guardant Health Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 18, 2026 2:28 AM UTC